Stabilizing and treating mental illnesses reduces the cost of treating associated medical problems, leading to a win-win situation, said Roger Kathol, MD, president of Cartesian Solutions, Inc., and adjunct professor of psychiatry at the University of Minnesota.
Stabilizing and treating mental illnesses reduces the cost of treating associated medical problems, leading to a win-win situation, said Roger Kathol, MD, president of Cartesian Solutions, Inc., and adjunct professor of psychiatry at the University of Minnesota.
Transcript
What are the health outcomes of integrating behavioral health services?
The outcome is, number one, that the mental health issues improve substantially or completely resolve. There are a number of people that have mental health or substance abuse conditions that will improve but not go away, and so maintaining and stabilizing them is an important component.
But then once they have an improvement, then the majority of the cost associated with mental health problems is not the mental health issues. It’s the use of medical services, which is about 4 times as much as the cost of the mental health services. So as you improve the mental health conditions so that patients are stabilized or the mental health problems are resolved, then the amount of service use on the medical side decreases, and the health problems that are commonly occurring in patients with mental health problems, such as chronic medical illnesses, tend to stabilize as well and it’s a win for everybody.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More